Response Genetics, Inc. (RGDX) Reports Wider Q2 Loss of $0.08/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Response Genetics, Inc. Announces Second Quarter 2014 Financial Results
August 14, 2014 7:00 AM EDTLOS ANGELES, Aug. 14, 2014 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2014.
Second Quarter 2014 Highlights:
Record ResponseDX® revenues increase 18% over Q2 2013 and 11% over Q1 2014 Volume increases 16% over Q1 2014 Gross margins increase to 40% Operating loss decreases 11% from Q1 2014Total revenue for the second quarter ended June 30, 2014 was $4.3 million compared to... More
